https://www.live-feeds.com/feed/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-winContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-winhttps://www.live-feeds.com/feed/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-win#u149887Fri, 23 Oct 2026 13:00:56 +0000Germany's Merck KGaA is buying Silence Therapeutics in an acquisition valued at $1.3 billion. The deal follows positive phase 2 results for Silence's lead small interfering RNA drug targeting the rare blood cancer polycythemia vera. The transaction expands Merck KGaA's rare disease buildout, hematology portfolio, and gene-silencing RNA capabilities. Silence Therapeutics stock surged 125 percent following the acquisition announcement. The agreement is scheduled to close in early 2027.Why it mattersSilence Therapeutics develops gene-silencing RNA technology and its lead asset has